Pasotuxizumab

Tax included
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).
MedChemExpress 
HY-P99802

Data sheet

Size
Multiple sizes
Reactivity
CD3
Application
Cancer-programmed cell death
CAS
1442657-12-6